Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology, Inc. reports that Executive Vice President and Chief Financial Officer Jason O’Byrne informed the company on July 20, 2026 that he will step down from his role effective August 3, 2026 to pursue another opportunity. The company states that his resignation is not due to any disagreement regarding operations, policies, or practices, and it has begun a search for a permanent successor.
On July 23, 2026, the Board appointed Brent Sabatini, CPA, MBA, currently Senior Vice President and Chief Accounting Officer, as interim principal financial officer, effective August 3, 2026. Sabatini, 52, has served as Vir’s Senior Vice President and Chief Accounting Officer since February 2023 and principal accounting officer since October 2024, and previously held finance leadership roles at Capsida Biotherapeutics and Amgen. He has no reportable related-party transactions, no special arrangements relating to his selection, no family relationships with directors or executives, and will receive no additional compensation for the interim role.
Vir Biotechnology, Inc. director Timothy Coughlin reported compensation-related equity grants. He acquired two awards of 8,000 shares of common stock each at no cost, in the form of restricted stock units under the company’s Equity Incentive Plan. He also received two stock option grants covering 16,000 shares each at an exercise price of $8.51 per share, expiring in 2036. Portions of the RSUs and options begin vesting on June 9, 2027, with remaining amounts vesting over time or in full by the earlier of that date or the next annual meeting of stockholders. Following these grants, one reported common stock position shows 16,000 shares held directly.
Vir Biotechnology, Inc. director Timothy Coughlin filed an initial Form 3 reporting his beneficial ownership of the company’s common stock. The filing shows he directly owns 0 shares of common stock following the reported position as of June 9, 2026.
Vir Biotechnology, Inc. announced that its Board of Directors increased in size from seven to eight members and appointed Timothy Coughlin, CPA, as a new Class III director effective June 9, 2026. He will serve on the Board until the company’s 2028 annual meeting of stockholders.
Coughlin was also appointed as Chair of the Audit Committee, giving him a key oversight role in the company’s financial reporting. He was not selected pursuant to any arrangement with another person, and the company reports no related party transactions requiring disclosure.
As a non-employee director, Coughlin will receive standard cash and equity compensation under Vir’s non-employee director compensation policy. On his appointment date, he received stock option and restricted stock unit awards under the company’s 2019 Equity Incentive Plan, and he entered into Vir’s standard indemnity agreement for directors.
Vir Biotechnology director Janet Napolitano sold 3,200 shares of Common Stock in an open-market transaction at $9.45 per share. After the sale, she directly holds 21,216 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 27, 2025.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an open-market sale of 379 shares of common stock at $9.45 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. After this small sale, he directly holds 61,902 shares.
The footnotes note that the 379 shares sold had been acquired on May 29, 2026 through an employee stock purchase program, indicating this filing reflects routine, pre-planned portfolio activity rather than a large discretionary transaction.
VIR submitted a Form 144 notice relating to proposed sales of Common Stock. The filing lists 379 shares acquired under the ESPP on 05/29/2026 (cash purchase) and shows a prior sale by Brent Sabatini on 03/23/2026 involving 7,711 shares for $70,324.32. The filing date appears as 06/01/2026 and the broker listed is Fidelity Brokerage Services LLC.
Vir Biotechnology director Charles Elliott Sigal reported equity awards and updated holdings. He received 8,000 restricted stock units under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received stock options for 16,000 shares at an exercise price of $9.10 per share, vesting on the same date and expiring on May 26, 2036. After these grants, he holds 39,806 shares of common stock directly and 10,000 shares indirectly through Sigal Family Investments, LLC, for which he disclaims beneficial ownership beyond his economic interest.